| Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II … M Debiec-Rychter, H Dumez, I Judson, B Wasag, J Verweij, M Brown, ... European journal of cancer 40 (5), 689-695, 2004 | 588 | 2004 |
| Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants M Debiec-Rychter, J Cools, H Dumez, R Sciot, M Stul, N Mentens, ... Gastroenterology 128 (2), 270-279, 2005 | 581 | 2005 |
| Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity M Debiec‐Rychter, B Wasag, M Stul, I De Wever, A Van Oosterom, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2004 | 268 | 2004 |
| Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor–associated PDGFRAD842V mutation B Dewaele, B Wasag, J Cools, R Sciot, H Prenen, P Vandenberghe, ... Clinical Cancer Research 14 (18), 5749-5758, 2008 | 150 | 2008 |
| Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site B Wasag, M Debiec-Rychter, P Pauwels, M Stul, H Vranckx, ... Modern Pathology 17 (8), 889-894, 2004 | 145 | 2004 |
| Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status A Wozniak, R Sciot, L Guillou, P Pauwels, B Wasag, M Stul, ... Genes, Chromosomes and Cancer 46 (3), 261-276, 2007 | 124 | 2007 |
| Mutations in gastrointestinal stromal tumors–a population‐based study from Northern Norway SE Steigen, TJ Eide, B Wasag, J Lasota, M Miettinen Apmis 115 (4), 289-298, 2007 | 116 | 2007 |
| Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors J Lasota, AJ vel Dobosz, B Wasag, A Wozniak, E Kraszewska, W Michej, ... Laboratory investigation 87 (10), 1029-1041, 2007 | 105 | 2007 |
| The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613 J Remon, J Menis, B Hasan, A Peric, E De Maio, S Novello, M Reck, ... Clinical lung cancer 18 (5), 583-588, 2017 | 99 | 2017 |
| European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer I Vergote, A González-Martín, I Ray-Coquard, P Harter, N Colombo, ... Annals of Oncology 33 (3), 276-287, 2022 | 85 | 2022 |
| Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrentLDLR mutations M Chmara, B Wasąg, M Żuk, J Kubalska, A Węgrzyn, ... Journal of applied genetics 51 (1), 95-106, 2010 | 83 | 2010 |
| The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases J Lasota, JF Fetsch, A Wozniak, B Wasag, R Sciot, M Miettinen The American journal of pathology 158 (4), 1223-1229, 2001 | 79 | 2001 |
| Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease M Gruchala, D Ciećwierz, B Wasag, R Targoński, W Dubaniewicz, ... American heart journal 145 (1), 125-131, 2003 | 76 | 2003 |
| The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t (7; 8)(q22; p11) B Wasag, E Lierman, P Meeus, J Cools, P Vandenberghe haematologica 96 (6), 922, 2011 | 75 | 2011 |
| Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach J Lasota, A Kowalik, B Wasag, ZF Wang, A Felisiak-Golabek, T Coates, ... The American journal of surgical pathology 38 (9), 1235-1241, 2014 | 74 | 2014 |
| Evaluation of NF2 and NF1 tumor suppressor genes in distinctive gastrointestinal nerve sheath tumors traditionally diagnosed as benign schwannomas: a study of 20 cases J Lasota, B Wasąg, A Dansonka-Mieszkowska, D Karcz, CL Millward, ... Laboratory investigation 83 (9), 1361-1371, 2003 | 74 | 2003 |
| Fumarase-deficient uterine leiomyomas: an immunohistochemical, molecular genetic, and clinicopathologic study of 86 cases M Miettinen, A Felisiak-Golabek, B Wasag, M Chmara, Z Wang, R Butzow, ... The American journal of surgical pathology 40 (12), 1661-1669, 2016 | 72 | 2016 |
| Colonic adenocarcinomas harboring NTRK fusion genes: a clinicopathologic and molecular genetic study of 16 cases and review of the literature J Lasota, M Chlopek, J Lamoureux, J Christiansen, A Kowalik, B Wasag, ... The American journal of surgical pathology 44 (2), 162-173, 2020 | 59 | 2020 |
| Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis B Wasag, M Niedoszytko, A Piskorz, M Lange, J Renke, E Jassem, ... Experimental hematology 39 (8), 859-865. e2, 2011 | 54 | 2011 |
| A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib A Mital, A Piskorz, K Lewandowski, B Wasąg, J Limon, A Hellmann European Journal of Haematology, 2011 | 54 | 2011 |
